von Hippel-Lindau tumor suppressor: not only HIF's executioner
about
Quantitative proteomics identifies the Myb-binding protein p160 as a novel target of the von Hippel-Lindau tumor suppressorTumor suppressor protein VHL inhibits Hedgehog-Gli activation through suppression of Gli1 nuclear localizationpVHL acts as an adaptor to promote the inhibitory phosphorylation of the NF-kappaB agonist Card9 by CK2Solution structure of the human ubiquitin-specific protease 15 DUSP domainVHL deletion impairs mammary alveologenesis but is not sufficient for mammary tumorigenesis.Genotype-phenotype correlation in ocular von Hippel-Lindau (VHL) disease: the effect of missense mutation position on ocular VHL phenotypeProteomic dissection of the von Hippel-Lindau (VHL) interactome.Microtubular stability affects pVHL-mediated regulation of HIF-1alpha via the p38/MAPK pathway in hypoxic cardiomyocytes.pVHL mediates K63-linked ubiquitination of nCLU.Ocular von Hippel-Lindau disease: clinical update and emerging treatments.The von Hippel-Lindau tumor suppressor protein: roles in cancer and oxygen sensing.Low VHL mRNA expression is associated with more aggressive tumor features of papillary thyroid carcinoma.The motor protein KIF14 inhibits tumor growth and cancer metastasis in lung adenocarcinomaFailure to prolyl hydroxylate hypoxia-inducible factor alpha phenocopies VHL inactivation in vivoRole of Ran-regulated nuclear-cytoplasmic trafficking of pVHL in the regulation of microtubular stability-mediated HIF-1α in hypoxic cardiomyocytesThe PCa Tumor Microenvironment.Hypoxia-inducible factor 1 activation from adipose protein 2-cre mediated knockout of von Hippel-Lindau gene leads to embryonic lethality.The interaction of the von Hippel-Lindau tumor suppressor and heterochromatin protein 1.Genetic modification of hypoxia signaling in animal models and its effect on cancer.EGLN3 prolyl hydroxylase regulates skeletal muscle differentiation and myogenin protein stability.BnRCH gene inhibits cell growth of Hela cells through increasing the G2 phase of cell cycle.von Hippel-Lindau-dependent patterns of RNA polymerase II hydroxylation in human renal clear cell carcinomasHypoxia-inducible factor linked to differential kidney cancer risk seen with type 2A and type 2B VHL mutations.Reversible binding of hemoglobin to band 3 constitutes the molecular switch that mediates O2 regulation of erythrocyte properties.Reconstruction of kidney renal clear cell carcinoma evolution across pathological stages.
P2860
Q21135547-DB324298-848F-4CEE-80CB-46EFEE8EFA45Q24315847-19E117C7-ECC0-4A0B-B31B-274E87159EFFQ24684757-6130E35E-D2A2-46FF-8CDF-7F99766C578CQ28282716-302AE364-A9E1-4223-BE22-85B0AA892D7CQ33816341-9EA77A48-D7B9-482B-94A7-FF37702AF910Q34135425-8DD2FEF6-4522-4EEE-92D2-47AD220E9384Q34218966-0251DAD6-0DEA-4787-B6C2-D40833210321Q34233804-9EE901D0-B542-4223-96DC-E58BA24A9326Q34245192-607DB0B0-1A94-4F8D-A8C6-C0E877C2BC36Q34459992-5A40F27F-80D6-443C-91B7-A6A18309ED8AQ34569380-40B5C2C8-9E92-4465-90EE-FE76A8B646A8Q34662980-63A20409-ABC2-4A46-9A23-9937FC7B8ADEQ34692260-278A2833-C55E-4323-8144-297DF6E31E37Q35065823-3C991DF5-F37F-492E-B7CA-AA469F131616Q35182984-72C9E964-3E58-4915-AD98-451DDC4275B9Q35603143-FD2A2789-4AB8-4475-8D9D-353F231E4D43Q35718056-42DC716E-4A41-44F4-8980-21683C58F627Q35742606-E74FFF43-CA3D-4153-92F4-1696E2295EE7Q38263349-004A215E-D603-4DAE-ADBD-282F194CD38BQ38303962-583C1B79-BD1C-4169-A47D-E7F732CCFC97Q39450806-7EAC94B8-FA66-4C05-9EB4-DFD64EFB76BDQ39639553-ED6486F5-D9A3-485E-AB32-4F88B779B93BQ40127751-C5165F2A-ACC2-4A25-9115-2B156D9E7D7BQ48327851-94481918-BA56-4347-964F-95E74B94D49DQ49789459-5BEC9EFB-7A48-4191-B16E-96405130D9A6
P2860
von Hippel-Lindau tumor suppressor: not only HIF's executioner
description
2004 nî lūn-bûn
@nan
2004 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
von Hippel-Lindau tumor suppressor: not only HIF's executioner
@ast
von Hippel-Lindau tumor suppressor: not only HIF's executioner
@en
von Hippel-Lindau tumor suppressor: not only HIF's executioner
@nl
type
label
von Hippel-Lindau tumor suppressor: not only HIF's executioner
@ast
von Hippel-Lindau tumor suppressor: not only HIF's executioner
@en
von Hippel-Lindau tumor suppressor: not only HIF's executioner
@nl
prefLabel
von Hippel-Lindau tumor suppressor: not only HIF's executioner
@ast
von Hippel-Lindau tumor suppressor: not only HIF's executioner
@en
von Hippel-Lindau tumor suppressor: not only HIF's executioner
@nl
P3181
P1476
von Hippel-Lindau tumor suppressor: not only HIF's executioner
@en
P2093
Jaroslaw Meller
Maria F Czyzyk-Krzeska
P3181
P356
10.1016/J.MOLMED.2004.02.004
P407
P577
2004-04-01T00:00:00Z